142 related articles for article (PubMed ID: 35058590)
1. Five ways to improve international comparisons of cancer survival: lessons learned from ICBP SURVMARK-2.
Andersson TM; Myklebust TÅ; Rutherford MJ; Møller B; Arnold M; Soerjomataram I; Bray F; Parkin DM; Lambert PC
Br J Cancer; 2022 May; 126(8):1224-1228. PubMed ID: 35058590
[TBL] [Abstract][Full Text] [Related]
2. Progress in cancer survival, mortality, and incidence in seven high-income countries 1995-2014 (ICBP SURVMARK-2): a population-based study.
Arnold M; Rutherford MJ; Bardot A; Ferlay J; Andersson TM; Myklebust TÅ; Tervonen H; Thursfield V; Ransom D; Shack L; Woods RR; Turner D; Leonfellner S; Ryan S; Saint-Jacques N; De P; McClure C; Ramanakumar AV; Stuart-Panko H; Engholm G; Walsh PM; Jackson C; Vernon S; Morgan E; Gavin A; Morrison DS; Huws DW; Porter G; Butler J; Bryant H; Currow DC; Hiom S; Parkin DM; Sasieni P; Lambert PC; Møller B; Soerjomataram I; Bray F
Lancet Oncol; 2019 Nov; 20(11):1493-1505. PubMed ID: 31521509
[TBL] [Abstract][Full Text] [Related]
3. Exploring the impact of cancer registry completeness on international cancer survival differences: a simulation study.
Andersson TM; Rutherford MJ; Myklebust TÅ; Møller B; Soerjomataram I; Arnold M; Bray F; Parkin DM; Sasieni P; Bucher O; De P; Engholm G; Gavin A; Little A; Porter G; Ramanakumar AV; Saint-Jacques N; Walsh PM; Woods RR; Lambert PC
Br J Cancer; 2021 Mar; 124(5):1026-1032. PubMed ID: 33293692
[TBL] [Abstract][Full Text] [Related]
4. Impact of variation in cancer registration practice on observed international cancer survival differences between International Cancer Benchmarking Partnership (ICBP) jurisdictions.
Eden M; Harrison S; Griffin M; Lambe M; Pettersson D; Gavin A; Brewster DH; Lin Y; Johannesen TB; Milne RL; Farrugia H; Nishri D; King MJ; Huws DW; Warlow J; Turner D; Earle CC; Peake M; Rashbass J
Cancer Epidemiol; 2019 Feb; 58():184-192. PubMed ID: 30639877
[TBL] [Abstract][Full Text] [Related]
5. Can different definitions of date of cancer incidence explain observed international variation in cancer survival? An ICBP SURVMARK-2 study.
Myklebust TÅ; Andersson T; Bardot A; Vernon S; Gavin A; Fitzpatrick D; Jerm MB; Rutherford M; Parkin DM; Sasieni P; Arnold M; Soerjomataram I; Bray F; Lambert PC; Møller B
Cancer Epidemiol; 2020 Aug; 67():101759. PubMed ID: 32544801
[TBL] [Abstract][Full Text] [Related]
6. Population-based cancer staging for oesophageal, gastric, and pancreatic cancer 2012-2014: International Cancer Benchmarking Partnership SurvMark-2.
Cabasag CJ; Arnold M; Piñeros M; Morgan E; Brierley J; Hofferkamp J; Kehoe S; Butler J; Bucher O; Bray F; Soerjomataram I; Parkin DM
Int J Cancer; 2021 Sep; 149(6):1239-1246. PubMed ID: 33990959
[TBL] [Abstract][Full Text] [Related]
7. Colon and rectal cancer survival in seven high-income countries 2010-2014: variation by age and stage at diagnosis (the ICBP SURVMARK-2 project).
Araghi M; Arnold M; Rutherford MJ; Guren MG; Cabasag CJ; Bardot A; Ferlay J; Tervonen H; Shack L; Woods RR; Saint-Jacques N; De P; McClure C; Engholm G; Gavin AT; Morgan E; Walsh PM; Jackson C; Porter G; Møller B; Bucher O; Eden M; O'Connell DL; Bray F; Soerjomataram I
Gut; 2021 Jan; 70(1):114-126. PubMed ID: 32482683
[TBL] [Abstract][Full Text] [Related]
8. International variation in oesophageal and gastric cancer survival 2012-2014: differences by histological subtype and stage at diagnosis (an ICBP SURVMARK-2 population-based study).
Arnold M; Morgan E; Bardot A; Rutherford MJ; Ferlay J; Little A; Møller B; Bucher O; De P; Woods RR; Saint-Jacques N; Gavin AT; Engholm G; Achiam MP; Porter G; Walsh PM; Vernon S; Kozie S; Ramanakumar AV; Lynch C; Harrison S; Merrett N; O'Connell DL; Mala T; Elwood M; Zalcberg J; Huws DW; Ransom D; Bray F; Soerjomataram I
Gut; 2022 Aug; 71(8):1532-1543. PubMed ID: 34824149
[TBL] [Abstract][Full Text] [Related]
9. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
10. A way to explore the existence of "immortals" in cancer registry data - An illustration using data from ICBP SURVMARK-2.
Andersson TM; Rutherford MJ; Myklebust TÅ; Møller B; Arnold M; Soerjomataram I; Bray F; Elkader HA; Engholm G; Huws D; Little A; Shack L; Walsh PM; Woods RR; Parkin DM; Lambert PC
Cancer Epidemiol; 2022 Feb; 76():102085. PubMed ID: 34954495
[TBL] [Abstract][Full Text] [Related]
11. The impact of reclassifying cancers of unspecified histology on international differences in survival for small cell and non-small cell lung cancer (ICBP SurvMark-2 project).
Morgan E; Arnold M; Rutherford MJ; Bardot A; Ferlay J; De P; Engholm G; Jackson C; Little A; Saint-Jacques N; Walsh P; Woods RR; O'Connell DL; Bray F; Parkin DM; Soerjomataram I
Int J Cancer; 2021 Sep; 149(5):1013-1020. PubMed ID: 33932300
[TBL] [Abstract][Full Text] [Related]
12. International variation in childhood cancer mortality rates from 2001 to 2015: Comparison of trends in the International Cancer Benchmarking Partnership countries.
Smith L; Stiller CA; Aitken JF; Hjalgrim LL; Johannesen T; Lahteenmaki P; McCabe MG; Phillips R; Pritchard-Jones K; Steliarova-Foucher E; Winther JF; Woods RR; Glaser AW; Feltbower RG
Int J Cancer; 2022 Jan; 150(1):28-37. PubMed ID: 34449879
[TBL] [Abstract][Full Text] [Related]
13. Comparison of liver cancer incidence and survival by subtypes across seven high-income countries.
Rutherford MJ; Arnold M; Bardot A; Ferlay J; De P; Tervonen H; Little A; Bucher O; St Jacques N; Gavin A; Engholm G; Møller B; O'Connell DL; Merrett N; Parkin DM; Bray F; Soerjomataram I
Int J Cancer; 2021 Dec; 149(12):2020-2031. PubMed ID: 34460109
[TBL] [Abstract][Full Text] [Related]
14. An International Consensus on Actions to Improve Lung Cancer Survival: A Modified Delphi Method Among Clinical Experts in the International Cancer Benchmarking Partnership.
Lynch C; Harrison S; Butler J; Baldwin DR; Dawkins P; van der Horst J; Jakobsen E; McAleese J; McWilliams A; Redmond K; Swaminath A; Finley CJ
Cancer Control; 2022; 29():10732748221119354. PubMed ID: 36269109
[TBL] [Abstract][Full Text] [Related]
15. Comparability of stage data in cancer registries in six countries: lessons from the International Cancer Benchmarking Partnership.
Walters S; Maringe C; Butler J; Brierley JD; Rachet B; Coleman MP
Int J Cancer; 2013 Feb; 132(3):676-85. PubMed ID: 22623157
[TBL] [Abstract][Full Text] [Related]
16. International benchmarking of childhood cancer survival by stage at diagnosis: The BENCHISTA project protocol.
Botta L; Gatta G; Didonè F; Lopez Cortes A; Pritchard-Jones K;
PLoS One; 2022; 17(11):e0276997. PubMed ID: 36327231
[TBL] [Abstract][Full Text] [Related]
17. Exploring the Role of Leadership in Facilitating Change to Improve Cancer Survival: An Analysis of Experiences in Seven High Income Countries in the International Cancer Benchmarking Partnership (ICBP).
Morris M; Seguin M; Landon S; McKee M; Nolte E
Int J Health Policy Manag; 2022 Sep; 11(9):1756-1766. PubMed ID: 34380203
[TBL] [Abstract][Full Text] [Related]
18. Variation in suspected cancer referral pathways in primary care: comparative analysis across the International Benchmarking Cancer Partnership.
Lynch C; Harrison S; Emery JD; Clelland C; Dorman L; Collins C; Johansen ML; Lawrenson R; Surgey A; Weller D; Jarbøl DE; Balasubramaniam K; Nicholson BD
Br J Gen Pract; 2023 Feb; 73(727):e88-e94. PubMed ID: 36127155
[TBL] [Abstract][Full Text] [Related]
19. Age disparities in stage-specific colon cancer survival across seven countries: An International Cancer Benchmarking Partnership SURVMARK-2 population-based study.
Pilleron S; Charvat H; Araghi M; Arnold M; Fidler-Benaoudia MM; Bardot A; Grønlie Guren M; Tervonen H; Little A; O'Connell DL; Gavin A; De P; Aagard Thomsen L; Møller B; Jackson C; Bucher O; Walsh PM; Vernon S; Bray F; Soerjomataram I
Int J Cancer; 2021 Apr; 148(7):1575-1585. PubMed ID: 33006395
[TBL] [Abstract][Full Text] [Related]
20. Cancer survival in Africa, central and south America, and Asia (SURVCAN-3): a population-based benchmarking study in 32 countries.
Soerjomataram I; Cabasag C; Bardot A; Fidler-Benaoudia MM; Miranda-Filho A; Ferlay J; Parkin DM; Ranganathan R; Piñeros M; Znaor A; Mery L; Joko-Fru YW; Dikshit R; Sankaranarayanan R; Swaminathan R; Bray F;
Lancet Oncol; 2023 Jan; 24(1):22-32. PubMed ID: 36603919
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
